Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | NMT1 | P30419 | 6/20 | 0.41 |
| ▸ | NMT2 | O60551 | 5/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10431763 | 0.89 | BCHE (0.44) | BCHESIGMAR1NMT1NMT2EPHX1 | |
| SCHEMBL8043092 | 0.78 | NAAA (0.36) | BCHEEPHX1 | |
| SCHEMBL9425883 | 0.77 | CTSS (0.45) | BCHESIGMAR1NMT1NMT2EPHX1 | |
| SCHEMBL8061028 | 0.77 | SIGMAR1 (0.40) | BCHESIGMAR1EPHX1 | |
| SCHEMBL8055986 | 0.77 | NAAA (0.37) | BCHEEPHX1 | |
| SCHEMBL10760331 | 0.76 | TSHR (0.52) | BCHESIGMAR1NMT1NMT2EPHX1 | |
| SCHEMBL4620970 | 0.74 | BCHE (0.45) | BCHESIGMAR1NMT1NMT2EPHX1 | |
| SCHEMBL4621576 | 0.74 | BCHE (0.45) | BCHESIGMAR1NMT1NMT2EPHX1 | |
| SCHEMBL8056055 | 0.73 | METAP2 (0.48) | BCHESIGMAR1NMT1NMT2EPHX1 | |
| SCHEMBL8055782 | 0.73 | NPC1 (0.34) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868032-B2 | Prostamide receptor antagonists | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20080096240-A1 | NOVEL PROSTAMIDE RECEPTOR ANTAGONISTS | WOODWARD DAVID F | 2008-04-24 | — | — | US | disclosed |
| US-6114534-A | REACTING A KETONE DERIVATIVE OF CARBAMOYL SUBSTITUTED HETEROCYCLE WITH PHOSPHORANE, FOLLOWED BY ACIDIFICATION TO FORM AN ANTICOAGULANT | ELI LILLY AND COMPANY (US) | 2000-09-05 | — | — | US | disclosed |
| US-6075147-A | OMEGA-PHENYL-OMEGA-(3-PYRIDYL)-OMEGA-ALKENOIC ACID DERIVATIVES BEARING A CARBAMOYL SUBSTITUTED OXAZOLYL OR OXAZOLINYL GROUP ON THE PHENYL RING IS USEFUL FOR THROMBOXANE RECEPTOR ANTAGONSIM OR THROMBOXANE SYNTHASE INHIBITOR | ELI LILLY AND COMPANY (US) | 2000-06-13 | — | — | US | disclosed |
| US-6031095-A | Intermediates in the preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5990308-A | Intermediates in the preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1999-11-23 | — | — | US | disclosed |
| US-5849922-A | Preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| US-5849766-A | Carbamoyl substituted heterocycles | ELI LILLY AND COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| US-5827868-A | Prostaglandin analogs | E. R. SQUIBB & SONS, INC. (US) | 1998-10-27 | — | — | US | disclosed |
| EP-0816361-A2 | Preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0811621-A2 | Carbamoyl substituted oxazoles as thromboxane receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| US-5550248-A | Substituted stryl heterocyclic amido prostaglandin analogs | E.R. SQUIBB & SONS, INC. (US) | 1996-08-27 | — | — | US | disclosed |
| US-5290799-A | 7-oxabicycloheptyl substituted heterocyclic thioamide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E. R. SQUIBB & SONS, INC. (US) | 1994-03-01 | — | — | US | disclosed |
| US-5280034-A | Bis-heterocyclic prostaglandin analogs | E. R. SQUIBB & SONS, INC. (US) | 1994-01-18 | — | — | US | disclosed |
| EP-0544287-A1 | Gem-dialkyl-7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E.R. SQUIBB & SONS, INC. (US) | 1993-06-02 | — | — | EP | disclosed |
| EP-0536713-A1 | Oxazole and imidazole derivatives as prostaglandin analogs | E.R. SQUIBB & SONS, INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| US-5153327-A | 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E. R. SQUIBB & SONS, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5100889-A | Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0476994-A1 | 7-Oxabicycloheptyl substituted heterocyclic thioamide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E.R. SQUIBB & SONS, INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0374952-A2 | 7-Oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E.R. SQUIBB & SONS, INC. (US) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096240-A1 | NOVEL PROSTAMIDE RECEPTOR ANTAGONISTS | PTGIR, PTGER1, TBXA2R | BCHE 3412/4885SIGMAR1 461/4885NMT1 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.